AMJEVITA

AbbVie's weak newer drug sales fan worries as Humira faces rivals

AbbVie pre-empted the so-called "sales cliff" from Humira patent expiry through its 2020 deal to buy Botox-maker Allergan, as well as betting on newer immunology drugs Skyrizi and Rinvoq. However, Rinvoq sales of $686 million missed estimates of $713.7 million in the first quarter, while Skyrizi's sales of $1.36 billion also fell short of expectations of $1.46 billion, according to Refinitiv IBES data.